POLE突变型子宫内膜癌非转移性淋巴结在PET/CT上18F-FDG摄取增高
回顾性纳入2018年7月至2023年8月术前接受FDG-PET/CT的102例子宫内膜癌患者,按分子分型分组。POLE突变型原发肿瘤SUVmax高于非POLE突变型(13.21±4.78 vs 9.82±3.78,p=0.001),非转移性淋巴结SUVmax亦更高(中位1.31 vs 1.06,p=0.003)。结论认为POLE突变型子宫内膜癌原发肿瘤SUVmax高,非转移性淋巴结也倾向摄取增高。
要点
- POLE突变型子宫内膜癌原发肿瘤SUVmax高于非POLE突变型(13.21±4.78 vs 9.82±3.78,p=0.001)。
- POLE突变型非转移性淋巴结SUVmax中位1.31(IQR 1.05-2.21),高于非POLE突变型的1.06(IQR 0.91-1.20),p=0.003。
- 多因素回归显示POLE状态是唯一与非转移性淋巴结SUVmax相关的因素(B=0.339,p=0.046)。
核心结论
- POLE突变型子宫内膜癌患者原发肿瘤SUVmax高,非转移性淋巴结也倾向显示摄取增高。
研究设计与样本
- 回顾性研究,纳入2018年7月至2023年8月术前接受18F-FDG-PET/CT的102例子宫内膜癌患者(平均年龄56.2±11.8岁),按分子分型分组,测量原发肿瘤和淋巴结SUVmax并与分子分型做相关分析。
关键影像表现/征象
- POLE突变型子宫内膜癌原发肿瘤SUVmax均值±SD为13.21±4.78,非POLE突变型为9.82±3.78,p=0.001。
- POLE突变型非转移性淋巴结SUVmax中位1.31(IQR 1.05-2.21),非POLE突变型中位1.06(IQR 0.91-1.20),p=0.003。
诊断标准与关键数值
- 多因素回归显示POLE状态与原发肿瘤SUVmax相关(B=2.30,p=0.031)。
- 多因素回归显示POLE状态是唯一与非转移性淋巴结SUVmax相关的因素(B=0.339,p=0.046),年龄、BMI、血糖水平、组织学类型和原发肿瘤大小均无显著关联。
临床应用与阅片要点
- 阅片时POLE突变型子宫内膜癌原发肿瘤可表现为较高的FDG摄取。
- POLE突变型子宫内膜癌的非转移性淋巴结也倾向显示FDG摄取增高,判读淋巴结时需结合分子分型。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: DNA polymerase epsilon (POLE) exonuclease domain-mutated endometrial cancer (EC) is associated with a favorable prognosis and significant immune cell infiltration. Cancers with significant immune cell infiltration often exhibit higher maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT). This study aimed to evaluate the correlation between POLE status and FDG-PET/CT imaging in patients with EC.
METHODS: This retrospective study enrolled 102 patients (mean age, 56.2 ± 11.8 years) with EC who underwent preoperative FDG-PET/CT between July 2018 and August 2023. Patients were categorized into molecular subtypes based on molecular profiling. SUVmax of the primary tumor and lymph nodes was measured, and correlations with molecular subtypes were examined.
RESULTS: The SUVmax in the primary tumor of POLE-mutated ECs was higher than that in non-POLE-mutated ECs (mean ± SD, 13.21 ± 4.78 vs 9.82 ± 3.78; p = 0.001). Multiple regression analysis showed that POLE status was associated with SUVmax in primary tumors (B = 2.30, p = 0.031). The SUVmax in non-metastatic lymph nodes of POLE-mutated ECs was higher than that in non-POLE-mutated ECs (median SUVmax, 1.31 [IQR, 1.05-2.21] vs. 1.06 [IQR, 0.91-1.20]; p = 0.003). Multiple regression analysis revealed that POLE status was the only factor associated with SUVmax in non-metastatic lymph nodes (B = 0.339, p = 0.046), while age, BMI, blood glucose level, histological type, and primary tumor size showed no significant association.
CONCLUSION: Patients with POLE-mutated EC exhibit high SUVmax in primary tumors and also tend to show elevated uptake in non-metastatic lymph nodes.
引用
- Kurihara M, Iwabuchi Y, Yamada Y, et al. Elevated 18F-FDG uptake in non-metastatic lymph nodes of POLE-mutated endometrial cancer on PET/CT. Eur J Radiol. 2025. PMID: 41435795. doi:10.1016/j.ejrad.2025.112620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。